Breaking News Instant updates and real-time market news.

NLNK

NewLink Genetics

$18.26

-0.76 (-4.00%)

07:03
04/21/17
04/21
07:03
04/21/17
07:03

NewLink Genetics to present two abstracts at ASCO 2017

NewLink Genetics reported that two abstracts will be presented at the 2017 American Society of Clinical Oncology, or ASCO, Annual Meeting in Chicago. Abstract 105 - A Phase 1b dose-escalation study of combined inhibition of IDO1 and PD-L1 in patients with locally advanced or metastatic solid tumors, to be presented by our partner on Sunday, June 4. Abstract 3066 - A Phase 2 randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer, to be presented on Monday, June 5.

  • 04

    May

  • 12

    May

  • 06

    Jun

NLNK NewLink Genetics
$18.26

-0.76 (-4.00%)

04/20/17
CANT
04/20/17
NO CHANGE
CANT
NewLink Genetics price target raised to $32 from $20 at Cantor
Cantor analyst Mara Goldstein raised her price target on NewLink, citing her "increased conviction about" its indoximod drug "and overall IDO program." The analyst thinks that the market is misinterpreting data presented on indoximod at AACR. Specifically, she says that the drug's 12% complete response rate validates it, given its 52% overall response rate and 73% disease control rate. She adds that the drug has better tolerability than the CTLA-4 and PD-L1 inhibitor combination., The analyst believes that this discrepancy could give indoximod "a significant advantage." Goldstein raised her price target on the stock to $32 from $20 and keeps a Buy rating.
04/06/17
STFL
04/06/17
NO CHANGE
Target $26
STFL
Buy
NewLink Genetics valuation disconnect 'egregious,' says Stifel
Stifel analyst Stephen Willey continues to believe the initial reaction to indoximod/pembrolizumab melanoma data and continued weakness is significantly overdone. Willey said NewLink is the exclusive owner of what is now the most-robust IDO-related data set generated to date and collaborator Genentech/Roche will present the most-comprehensive IDO-related data set across multiple tumor types with immunological correlate data in mid-FY17, which could be a catalyst for a go-forward decision into a large registrational Phase 3 development program. The analyst would like to hear management articulate a clear registrational development plan before assigning a significant value related to indoximod, but even without this, he believes the valuation disconnect remains "egregious" and reiterates his Buy rating and $26 price target on shares.
04/05/17
RHCO
04/05/17
NO CHANGE
RHCO
NewLink Genetics data encouraging, says SunTrust
SunTrust analyst Peter Lawson says that interim data on NewLink's Indoximod is "encouraging." The analyst says that "Indoximod + IO has comparable efficacy to approved IO combos, but is more tolerable," and he expects the data to improve going forward. He adds that the drug's "durability is encouraging." He reiterates a $30 price target and a Buy rating on the shares. ,
04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.

TODAY'S FREE FLY STORIES

MU

Micron

$32.50

0.765 (2.41%)

15:05
06/26/17
06/26
15:05
06/26/17
15:05
Options
Micron call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 29

    Aug

MAR

Marriott

$104.06

0.17 (0.16%)

15:00
06/26/17
06/26
15:00
06/26/17
15:00
Conference/Events
Marriott management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.92

1.38 (14.47%)

14:54
06/26/17
06/26
14:54
06/26/17
14:54
Periodicals
Apple only leasing six cars from Hertz, CNBC says »

After Bloomberg reported…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.92

1.38 (14.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NG

NovaGold

$4.50

-0.075 (-1.64%)

14:49
06/26/17
06/26
14:49
06/26/17
14:49
Options
NovaGold options imply 6.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.84

1.3002 (13.63%)

14:47
06/26/17
06/26
14:47
06/26/17
14:47
Periodicals
Hertz to manage small self-driving car fleet for Apple, Bloomberg says »

Apple (AAPL) is leasing a…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.84

1.3002 (13.63%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

CAR

Avis Budget

$24.24

1.23 (5.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

OTIC

Otonomy

$18.75

1 (5.63%)

14:46
06/26/17
06/26
14:46
06/26/17
14:46
Conference/Events
Otonomy to hold a breakfast meeting »

Chief Scientific Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

, WMT

Wal-Mart

$75.61

0.77 (1.03%)

14:44
06/26/17
06/26
14:44
06/26/17
14:44
Hot Stocks
Quest Diagnostics, Wal-Mart team up to offer healthcare services »

Quest Diagnostics (DGX)…

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

WMT

Wal-Mart

$75.61

0.77 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

EBSB

Meridian Bancorp

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Upgrade
Meridian Bancorp rating change  »

Meridian Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$14.17

-0.21 (-1.46%)

, INTC

Intel

$34.19

-0.17 (-0.49%)

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Recommendations
AMD, Intel analyst commentary  »

Goldman reiterates Sell…

AMD

AMD

$14.17

-0.21 (-1.46%)

INTC

Intel

$34.19

-0.17 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Aug

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

, PRXL

Parexel

$86.80

-0.31 (-0.36%)

14:41
06/26/17
06/26
14:41
06/26/17
14:41
Hot Stocks
Kitov sees formal filing of NDA for KIT-302 by end of Q3 »

Kitov Pharmaceuticals…

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

PRXL

Parexel

$86.80

-0.31 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

RAD

Rite Aid

$3.93

0.8199 (26.36%)

14:40
06/26/17
06/26
14:40
06/26/17
14:40
Options
Heavy trading in RiteAid as shares surge »

Heavy trading in RiteAid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:40
06/26/17
06/26
14:40
06/26/17
14:40
General news
Treasury Action: yields remain slightly lower »

Treasury Action: yields…

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:39
06/26/17
06/26
14:39
06/26/17
14:39
Conference/Events
EVINE Live management to meet with Craig-Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:38
06/26/17
06/26
14:38
06/26/17
14:38
Conference/Events
EVINE Live management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

HTZ

Hertz

$10.19

0.65 (6.81%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Technical Analysis
Technical View: Hertz spikes higher, levels to watch »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAG

AMAG Pharmaceuticals

$18.35

0.15 (0.82%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Recommendations
AMAG Pharmaceuticals analyst commentary  »

AMAG delay for Makena…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$45.60

5.58 (13.94%)

14:30
06/26/17
06/26
14:30
06/26/17
14:30
Options
Timely call activity in Fabrinet »

Timely call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 29

    Aug

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.24

0.7 (7.34%)

14:26
06/26/17
06/26
14:26
06/26/17
14:26
Periodicals
Breaking Periodicals news story on Apple, Hertz »

Hertz to manage small…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.24

0.7 (7.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GM

General Motors

$34.49

0.29 (0.85%)

14:25
06/26/17
06/26
14:25
06/26/17
14:25
Conference/Events
General Motors to host a conference call »

EVP & CFO Chuck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

T

AT&T

$38.15

0.2001 (0.53%)

14:20
06/26/17
06/26
14:20
06/26/17
14:20
Options
Calendar call spread in AT&T rolls short position from July to September »

Calendar call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:19
06/26/17
06/26
14:19
06/26/17
14:19
General news
Averages mixed but internals strong »

The averages remain mixed…

$NSD

NASDAQ Market Internals

14:17
06/26/17
06/26
14:17
06/26/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/26/17
06/26
14:16
06/26/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
06/26/17
06/26
14:15
06/26/17
14:15
General news
NY Fed's overnight reverse repo totaled $185.2 B, with 49 counterparties »

NY Fed's overnight…

IAC

IAC

$104.84

0.3 (0.29%)

, NFLX

Netflix

$158.02

3.13 (2.02%)

14:13
06/26/17
06/26
14:13
06/26/17
14:13
Hot Stocks
Vimeo cancels plans for subscription video service »

IAC (IAC)-owned video…

IAC

IAC

$104.84

0.3 (0.29%)

NFLX

Netflix

$158.02

3.13 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 17

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.